Whats new
Whats new.
Bell Potter - ASCO data further builds case for efti+Keytruda, with HNSCC looking more attractive (Analyst: Tanushree Jain)
June 3rd 2020
For a copy of this research report please contact tnjain@bellpotter.com.au
Whats new
June 3rd 2020
For a copy of this research report please contact tnjain@bellpotter.com.au